Previous 10 | Next 10 |
DURECT Corporation (NASDAQ: DRRX) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 9.88% on the day to $4.45. DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigeneti...
DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis PR Newswire Data expands upon previously reported results, including individual patient data, addition...
2023-04-03 08:55:43 ET Summary DRRX is a forever laggard company. In 2021, I noted its strong phase 2a data. There's phase 2b data this year, but the market is completely ignoring this stock. More than two years ago, when I last covered DURECT Corporation ( DRR...
2023-03-24 06:30:57 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks aren’t for everyone. They require some additional research and as an investor you have to be comfortable having product pipelines with a long pathway to market. Biotec...
2023-03-21 18:01:56 ET DURECT ( NASDAQ: DRRX ) on Tuesday announced that Gail Maderis has assumed the role of chair of the Board, effective March 17, 2023. Maderis succeeds David Hoffmann as chair of the board. Hoffman has decided no...
DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board PR Newswire CUPERTINO, Calif. , March 21, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of th...
DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference PR Newswire CUPERTINO, Calif. , March 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown , President and CEO and additional m...
2023-03-07 18:46:05 ET DURECT Corp (DRRX) Q4 2022 Earnings Conference Call March 07, 2023, 16:30 ET Company Participants Timothy Papp - CFO & Secretary James Brown - Co-Founder, CEO, President & Director Norman Sussman - Chief Medical Officer Keith Lu...
2023-03-07 16:10:11 ET Durect press release ( NASDAQ: DRRX ): Q4 GAAP EPS of -$0.46 beats by $0.09 . Revenue of $3.32M (-54.5% Y/Y) misses by $0.16M . For further details see: Durect GAAP EPS of -$0.46 beats by $0.09, revenue of $3.32M misses by $0.16M
DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update PR Newswire - Webcast of Earnings Call Today, March 7 th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in 2023 CUPERTINO, Ca...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...